Hollencrest Capital Management Increases Position in Humana Inc. (NYSE:HUM)

Hollencrest Capital Management grew its holdings in Humana Inc. (NYSE:HUM) by 23.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,507 shares of the insurance provider’s stock after buying an additional 470 shares during the period. Hollencrest Capital Management’s holdings in Humana were worth $663,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Riverview Trust Co purchased a new position in shares of Humana in the 1st quarter worth approximately $34,000. Garde Capital Inc. acquired a new position in shares of Humana in the 1st quarter valued at $36,000. Transce3nd LLC acquired a new position in Humana during the fourth quarter worth $38,000. Whipplewood Advisors LLC grew its holdings in shares of Humana by 639.1% during the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider’s stock worth $45,000 after buying an additional 147 shares in the last quarter. Finally, Colonial Trust Advisors grew its stake in shares of Humana by 4,500.0% in the 4th quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider’s stock valued at $47,000 after buying an additional 180 shares during the period. Institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on HUM. Guggenheim started coverage on shares of Humana in a report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 target price on the stock. Oppenheimer raised their target price on Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a report on Thursday, May 1st. Raymond James Financial raised Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target for the company in a research note on Thursday, May 1st. Barclays set a $268.00 price objective on shares of Humana and gave the company an “equal weight” rating in a research note on Thursday, June 12th. Finally, Robert W. Baird upped their price target on Humana from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, April 15th. Seventeen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $279.81.

Humana Stock Performance

NYSE:HUM opened at $222.54 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The firm has a market capitalization of $26.86 billion, a price-to-earnings ratio of 15.76, a PEG ratio of 1.55 and a beta of 0.44. The company’s 50-day moving average is $235.46 and its two-hundred day moving average is $257.46. Humana Inc. has a 1-year low of $212.45 and a 1-year high of $406.46.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $7.23 EPS. Analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.